Patents Assigned to iNtRON Biotechnology, Inc.
  • Patent number: 11452757
    Abstract: A pharmaceutical composition for treating Gram negative bacteria-associated infections includes an antibacterial protein that includes at least one selected from the group of a protein having the amino acid sequence as set forth in SEQ ID NO: 1, a protein having the amino acid sequence as set forth in SEQ ID NO: 2, a protein having the amino acid sequence as set forth in SEQ ID NO: 3, a protein having the amino acid sequence as set forth in SEQ ID NO: 4, a protein having the amino acid sequence as set forth in SEQ ID NO: 5, a protein having the amino acid sequence as set forth in SEQ ID NO: 6, a protein having the amino acid sequence as set forth in SEQ ID NO: 7, and a protein having the amino acid sequence as set forth in SEQ ID NO: 8. A method of preparing the antibacterial protein is also disclosed.
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: September 27, 2022
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Jeong Won Park, Ji Hyun Kim, Saet Byeol Kim, Sang Hyeon Kang
  • Patent number: 11351210
    Abstract: The present invention relates to Siphoviridae bacteriophage Lac-GAP-3 (Accession Number KCTC 12816BP) having the ability to specifically kill Lactococcus garvieae bacteria and a genome represented by SEQ ID NO: 1 and isolated from nature, and a method for prevention and treatment of Lactococcus garvieae bacterial infection by using a composition containing the same bacteriophage as an effective ingredient.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: June 7, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Soon Hye Hwang, Hyun Min Song, Sang Hyeon Kang
  • Patent number: 11324841
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly an MRI contrast agent derived from nanoparticle that is porous first metal-doped second metal oxide nanoparticle with a central cavity, and a method for producing the same. The MEI contrast agent made in accordance with the present invention can be used not only as a drug-delivery agent for therapy but also as an MRI contrast agent for diagnosis.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: May 10, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Kwang Yeol Lee, Min Sik Kim, Taek Hoon Kim, Ngoc Phan Vu
  • Patent number: 11229677
    Abstract: A method of treating staphylococcal infections includes administering to a subject an effective amount of an antibacterial composition having a broad bactericidal activity. The antibacterial composition includes a first antibacterial protein consisting of the amino acid sequence as set forth in SEQ. ID. NO: 1 and/or a second antibacterial protein consisting of the amino acid sequence as set forth in SEQ. ID. NO: 2.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: January 25, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Gi Mo Jung, Sang Hyeon Kang
  • Patent number: 11219698
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly a metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent that can be used not only as a T1 MRI contrast agent but also as a T2 MRI contrast agent, and a method for producing the same. The metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent can provide more accurate and detailed information associated with disease than single MRI contrast agent by the beneficial contrast effects in both T1 imaging with high tissue resolution and T2 imaging with high feasibility on detection of a lesion.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: January 11, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Kwang Yeol Lee, Min Sik Kim, Taek Hoon Kim, Ngoc Phan Vu
  • Patent number: 11020442
    Abstract: The present invention relates to: Podoviridae bacteriophage Vib-PAP-2 (accession number KCTC 12910BP) which has the capability to specifically destroy Vibrio parahaemolyticus, is characterized by having a genome represented by SEQ ID NO: 1, and is isolated from nature; and a method for preventing and treating Vibrio parahaemolyticus infections, using a composition containing bacteriophage Vib-PAP-2 as an active ingredient.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: June 1, 2021
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Soon Hye Hwang, Sang Hyeon Kang
  • Patent number: 10941172
    Abstract: Described is heme iron having Chemical Formula 1 not derived from porcine blood and a method of preparing the same, and more particularly to a method of chemically preparing heme iron having Chemical Formula 1 not derived from porcine blood, a method of preparing a salt thereof, and an iron supplement containing the salt thus prepared as an active ingredient:
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: March 9, 2021
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Jung In Pyo, Soon Hye Hwang, Soo Youn Jun, Sang Hyeon Kang
  • Patent number: 10898531
    Abstract: The present invention relates to a Myoviridae bacteriophage Vib-PAP-5 (accession number KCTC 13029BP) isolated from nature characterized by having a capability for specifically killing Vibrio parahaemolyticus bacteria and having a genome expressed by the SEQ ID NO:1, and to a method for preventing and treating infections from Vibrio parahaemolyticus bacteria by means of a composition comprising the Myoviridae bacteriophage Vib-PAP-5 as an active ingredient.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: January 26, 2021
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, An Sung Kwon
  • Patent number: 10894068
    Abstract: The present invention relates to a Podoviridae bacteriophage Bor-BRP-1 (accession no. KCTC 12705BP) isolated from nature, which has an ability to specifically kill Bordetella bronchiseptica bacteria and has a genome represented by SEQ ID NO: 1; and a method for preventing and treating infection with Bordetella bronchiseptica bacteria using a composition comprising the same as an active ingredient.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: January 19, 2021
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Suk Hwang Park, Byung Kuk Kim, Sang Hyeon Kang
  • Publication number: 20210008228
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly an MRI contrast agent derived from nanoparticle that is porous first metal-doped second metal oxide nanoparticle with a central cavity, and a method for producing the same. The MEI contrast agent made in accordance with the present invention can be used not only as a drug-delivery agent for therapy but also as an MRI contrast agent for diagnosis.
    Type: Application
    Filed: July 30, 2020
    Publication date: January 14, 2021
    Applicant: INTRON BIOTECHNOLOGY, INC.
    Inventors: Kwang Yeol LEE, Min Sik Kim, Taek Hoon Kim, Ngoc Phan Vu
  • Publication number: 20210000983
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly a metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent that can be used not only as a T1 MRI contrast agent but also as a T2 MRI contrast agent, and a method for producing the same. The metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent can provide more accurate and detailed information associated with disease than single MRI contrast agent by the beneficial contrast effects in both T1 imaging with high tissue resolution and T2 imaging with high feasibility on detection of a lesion.
    Type: Application
    Filed: July 20, 2020
    Publication date: January 7, 2021
    Applicant: INTRON BIOTECHNOLOGY, INC.
    Inventors: Kwang Yeol Lee, Min Sik Kim, Taek Hoon Kim, Ngoc Phan Vu
  • Patent number: 10759831
    Abstract: Provided are a novel peptide compound, a method of producing the same, and use of the peptide compound. Since the peptide compound has anticancer activity, the peptide compound may be used for the prevention or treatment of cancer.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: September 1, 2020
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Jong Heon Shin, Ki Bong Oh, Dong Chan Oh, Sang Kook Lee, Lijuan Liao, Min Jung You
  • Patent number: 10751377
    Abstract: The present invention relates to: Podoviridae bacteriophage Vib-PAP-1 (accession number KCTC 12817BP) which has the capability to specifically destroy Vibrio parahaemolyticus, is characterized by having a genome represented by SEQ ID NO: 1, and is isolated from nature; and a method for preventing and treating Vibrio parahaemolyticus infections, using a composition containing bacteriophage Vib-PAP-1 as an active ingredient.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: August 25, 2020
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Soon Hye Hwang, Sang Hyeon Kang
  • Patent number: 10722544
    Abstract: The present invention relates to a Siphoviridae bacteriophage Str-INP-1 (Accession NO: KCTC 12687BP) that is isolated from the nature and can kill specifically Streptococcus iniae cells, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1, and a method for preventing and treating the infections of Streptococcus iniae using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: July 28, 2020
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Hyun Min Song, Sang Hyeon Kang
  • Patent number: 10696989
    Abstract: The present invention relates to heme iron not derived from porcine blood and a method of preparing the same, and more particularly to a method of biologically preparing heme iron not derived from porcine blood, a method of preparing a salt thereof, and an iron supplement containing the salt thus prepared as an active ingredient.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: June 30, 2020
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Jung In Pyo, Soon Hye Hwang, Soo Youn Jun, Sang Hyeon Kang
  • Patent number: 10618934
    Abstract: Provided are a novel peptide compound, a method of producing the same, and use of the peptide compound. Since the peptide compound has anticancer activity, the peptide compound may be used for the prevention or treatment of cancer.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: April 14, 2020
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Jong Heon Shin, Ki Bong Oh, Dong Chan Oh, Sang Kook Lee, Lijuan Liao, Min Jung You
  • Patent number: 10568917
    Abstract: The present invention relates to: Myoviridae bacteriophage Pas-MUP-1 (accession number KCTC 12706BP) which has the capability to specifically destroy Pasteurella multocida, is characterized by having a genome represented by SEQ ID NO: 1, and is isolated from nature; and a method for preventing and treating Pasteurella multocida infections, using a composition containing bacteriophage Pas-MUP-1 as an active ingredient.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: February 25, 2020
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Dong Min Kang, Sang Hyeon Kang
  • Patent number: 10337044
    Abstract: Vectors expressing kanA-kanB-kanK and other kanamycin production-related genes, Streptomyces species recombinant bacteria transformed with the vectors, a method of producing kanamycin antibiotics by the bacteria, and a new kanamycin compound produced by the bacterium are provided. With the use of the recombinant bacteria of the present invention, the direct fermentative biosynthesis of amikacin and tobramycin as semi-synthetic kanamycins is possible, and the yield of kanamycin B as a precursor of the semi-synthetic kanamycin is improved.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: July 2, 2019
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Yeo Joon Yoon, Sung Ryeol Park, Je Won Park, Jae Kyung Sohng
  • Publication number: 20190183803
    Abstract: A freeze-dried formulation includes an antibacterial protein having killing activity specific to at least one of or all following species: Staphylococcus arlettae, Staphylococcus aureus, Staphylococcus auricularis, Staphylococcus carnosus, Staphylococcus carprae, Staphylococcus chromogenes, Staphylococcus cohnii, Staphylococcus delphini, Staphylococcus epidermidis, Staphylococcus equorum, Staphylococcus gallinarum, Staphylococcus hemolyticus, Staphylococcus hominis, Staphylococcus intermedius, Staphylococcus kloosii, Staphylococcus lentus, Staphylococcus lugdunensis, Staphylococcus muscae, Staphylococcus pasteuri, Staphylococcus saprophyticus, Staphylococcus warneri, and Staphylococcus xylosus; a poloxamer; a sugar, and an amino acid.
    Type: Application
    Filed: January 9, 2017
    Publication date: June 20, 2019
    Applicant: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun YOON, Soo Youn JUN, Gi Mo JUNG, Sang Hyeon KANG
  • Patent number: 10265356
    Abstract: The present invention relates to a Myoviridae bacteriophage Esc-COP-4 that is isolated from the nature and can kill specifically enteroinvasive E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12663BP), and a method for preventing and treating the infections of enteroinvasive E. coli using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 23, 2019
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Byung Kuk Kim, Hee Jeong Shin, Dong Min Kang